share_log

ResMed Shares Are Trading Lower After Rival Eli Lilly Received Approval for Zepbound as an Obstructive Sleep Apnea Treatment for Obese Adults.

ResMed Shares Are Trading Lower After Rival Eli Lilly Received Approval for Zepbound as an Obstructive Sleep Apnea Treatment for Obese Adults.

瑞思迈的股票因竞争对手礼来获得批准将Zepbound作为肥胖成年人阻塞性睡眠呼吸暂停治疗而下跌。
Benzinga ·  12/24 00:23

ResMed Shares Are Trading Lower After Rival Eli Lilly Received Approval for Zepbound as an Obstructive Sleep Apnea Treatment for Obese Adults.

竞争对手礼来公司获准将Zepbound作为肥胖成年人的阻塞性睡眠呼吸暂停治疗药物后,瑞思迈股价走低。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发